The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD);Wplyw leczenia formoterolem, formoterolem i tiotropium, formoterolem z wziewnym glikokortykosteroidem i tiotropium na czynność płuc, tolerancję wysilku i proste, poranne czynności u chorych na przewleklą obturacyjną chorobę pluc (POChP)

Pneumonologia i Alergologia Polska

Volumn 80, Issue 3, 2012, Pages 255-262

  Szmidt, Miroslaw ^a  

^a Wydzial Nauk Biomedycznych i Ksztalcenia Podyplomowego Uniwersytetu Medycznego w odzi   (Poland)

Author keywords

Bronchodilators; COPD; Morning everyday activities

Indexed keywords

BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE; FORMOTEROL; GLUCOCORTICOID; SCOPOLAMINE DERIVATIVE; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DAILY LIFE ACTIVITY; DRUG COMBINATION; DRUG EFFECT; EXERCISE TOLERANCE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; ETHANOLAMINES; EXERCISE TOLERANCE; GLUCOCORTICOIDS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 84861428957     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2007. www.goldcopdcom/Last accessed: March 2009. Last updated: 2008.
2. Lotvall J. Pharmacological similarities and differences between beta 2-agonists. Respir. Med. 2001; 955: S7-11.
3. Disse B., Speck G.A., Rominger K.L. i wsp. Tiotropium (Spiriva) mechanistical consideration and clinical profile in obstructive lung disease. Life. Sci. 1999; 64: 457-464.
4. Calverley P.M., Lee A., Towse L. i wsp. Effect of tiotropium bromide on circadian variation in air flow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58: 855-860.
5. van Noord J.A., Aumann J.L., Janssen E. i wsp. Effect of tiotropium with or without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-517.
6. Bestall J.C., Paul E.A., Garrod R. i wsp. Usefullness of the Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586.
7. Pitta F., Trooster T., Spriut M. i wsp. Characterististics of physical activities in daily life in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Care. Med. 2005; 171: 972-977.
8. Partridge M.R., Miravitlles M., Stahl E. i wsp. Development and validation of the Capacity of Daily Living during the Morning Questionaire and the Global Chest Symptoms Questionaire in COPD. Eur. Respir. J. 2010; 36: 96-104.
9. Partidge M.R., Karlsson N., Small J.R. Patients insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Current. Medical Research and Opinion 2009; 25: 2043-2048.
10. Vogelmeier C., Partridge M., Miravitlles M. i wsp. Perception of Symptom Variability in Patients with Severe COPD: Impact on Morning Activities and Therapeutic Behaviour. Am. J. Respir. Crit. Care. Med. 2010; A.5957.
11. Partridge M.R., Schuermann W., Beckman O. i wsp. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther. Adv. Respir. Dis. 2009; 3: 1-11.
12. Tzani P., Crisafulli E., Nicolini G. i wsp. Reduction in air trapping and dyspnea with an extrafine combination of beclomethasone and formoterol in COPD. ERS Annual Congress 2010, P120416.
13. Calverley P.M.A., Kuna P., Monso E. i wsp. Beclomethasone formoterol in the management of COPD: a randomized controlled trial 2010; 104: 1858-1868.
14. O'Donnell D.E. Assessment of bronchodilator efficacy in symptomatic COPD. Is spirometry useful? Chest. 2000; 117: 42-47.
15. O' Donnell D.E. Implications clinique de la distension thoracique, ou qaund la physiopathologie change la prise en charge therapeuthique full text in english on wwww.emconsulte.com/revue/rmr. Rev. Mal. Respir. 2008; 25: 1305-1318.
16. Parker C.M., Voduc N., Aaron S.D. i wsp. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur. Respir. J. 2005; 26: 420-428.
17. Lougheed M.D., Fisher T., O'Donnell D.E. Dynamic hyperinflation during bronchoconstriction in asthma: implications for symptom perception. Chest. 2006; 130: 1072-1081.
18. Casanowa C., Cote C., de Torres J.P. i wsp. Inspiratory to total lung capacity ratio predicts mortality in patients with chronic obstructive disease. Am. J. Respir. Crit. Care. Med. 2005; 171: 591-597.
19. Hannink J.D.C., van Helvoort H.A.C., Dekhuijzen P.N.R., Heijdra I.F. Dynamic hyperinflation during daily activities: does COPD global initiative for chronic obstructive lung disease stage matter? Chest. 2010; 137: 1116-1121.
20. Di Marco F., Milic-Emili J., Boveri B., Carlucci P., i wsp. Effect of inhaled bronchodilators on respiratory capacity and dyspnea at rest. Eur. Respir. J. 2003; 21: 86-94.
21. 1 reversibility. Current. Medical. Research. Opinion 2004; 20: 581-586.
22. Cote C., Pearle J.L., Sharafkhaneh A., Spangenthal S. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm. Pharmacol. Ther. 2009; 22: 44-49.
23. Rabe K.F., Timmer W., Sagkriotis A., Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134: 255-262.
24. Berton D.C., Reis M., Siqueira A.C.B. i wsp. Effect of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir. Med. 2010; 104: 1288-1296.
25. Tashkin D.P., Pearle J., Iezzoni D., Varghese S.T. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009; 6: 17-25.
26. Tashkin D.P., Varghese S.T. Combined treatment with formoterol and tiotropium is more efficatious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled coricosteroid use, base line severity, or gender. Pulm. Pharmacol. Ther. 2011; 24: 147-152.
27. Terzano C., Petroianni A., Conti V., Ceccarelli D. i wsp. Rational timing of combination therapy with tiotropium and formoterol in moderate to severe COPD. Respir. Med. 2008; 102: 1701-1707.
28. Calverley P.M., Boonsawat W., Cseke Z. i wsp. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 912-919.
29. Szafrański W., Cukier A., Ramirez A. i wsp. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74-81.
30. Calverley P.M.A., Paulwels R., Vestbo J. i wsp. Combined salmeterol and fluticasone in the treatment of chronic pulmonary disease: a randomized, controlled trial. Lancet. 2003; 361: 449-456.
31. Calverley P.M.A., Anderson J.A., Celli M.A. i wsp. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Eng. J. Med. 2007; 356: 775-789.
32. Welte T., Miravitlles M., Hernandez P. i wsp. Efficacy and tolerability of budesonide/ formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 2009; 180: 741-750.
33. McIvor R.A. Nowy długodziałaja{ogonek}cy beta 2-mimetyk wziewny stosowany raz dziennie-jaka{ogonek} role{ogonek} odegra w leczeniu POChP? Medycyna Praktyczna 2011; 1: 26-28.
34. Dahl R., Chung K.F., Buhl R. i wsp. Efficacy of a new once-daily long-acting inhaled beta2 agonist indacaterol versus twice--daily formoterol in COPD. Thorax 2010; 65: 473-479.